Stoneridge Investment Partners’s AbbVie ABBV Stock Holding History

Stoneridge Investment Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08M	Buy	+4,314	New	+$928K	0.71%	28
2015 Q1	–	Sell	-83,284	Closed	-$5.45M	–	266
2014 Q4	$5.45M	Sell	83,284 -700	-0.8%	-$44.1K	0.72%	35
2014 Q3	$4.85M	Buy	83,984 +69,705	+488%	+$3.87M	0.72%	37
2014 Q2	$806K	Buy	+14,279	New	+$749K	0.12%	164
2013 Q4	–	Sell	-327,322	Closed	-$14.6M	–	205
2013 Q3	$14.6M	Buy	327,322 +214,932	+191%	+$9.53M	3.2%	4
2013 Q2	$4.65M	Buy	+112,390	New	+$4.92M	1.08%	32

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Stoneridge Investment Partners's ABBV Position: Q2 2026 in Review

Stoneridge Investment Partners opened a new position in AbbVie (ABBV) in Q2 2026: 4,314 shares worth $1.08M. The stake represents 0.71% of the portfolio and ranks #28 among its holdings. This is a return to the name: Stoneridge Investment Partners previously reported a position in ABBV as recently as Q4 2014.

Stoneridge Investment Partners first reported a position in ABBV in Q2 2013 and has held it in 6 quarters since. The position peaked at $14.6M in Q3 2013. 4,214 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Stoneridge Investment Partners held 4,314 shares of AbbVie worth $1.08M as of Q2 2026.
AbbVie was a new Stoneridge Investment Partners position in Q2 2026.
AbbVie made up 0.71% of Stoneridge Investment Partners's portfolio in Q2 2026, its #28 holding.
Stoneridge Investment Partners first reported a position in AbbVie in Q2 2013 and has held it in 6 quarters since.
Stoneridge Investment Partners's AbbVie position peaked at $14.6M in Q3 2013.
4,214 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Stoneridge Investment Partners's 13F filing for Q2 2026, filed 6 Aug 2026.